New results from a pooled analysis of patients with previously treated EGFR-mutated NSCLC in the TROPION-Lung05 and TROPION-Lung01 trials will be featured in a late-breaking presentation at the ...

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 ...

Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient ...

in patients with resected glioblastoma in September 2024 at the European Society for Medical Oncology (ESMO) Congress and in November at the Society for Immunotherapy of Cancer (SITC) and the Society ...

EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...

BillionToOne, a next-generation molecular diagnostics company, announces three new executive appointments to support its expanding prenatal screening and oncology diagnostics business. Judy Wong joins ...

A nurse-led service at Oxford University Hospitals has been praised for its "safe, effective, and highly efficient" patient care.

CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter ...